Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reputation and precedent in the bevacizumab decision.

× No keyword cloud information.

19 in total

1. How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab.

Authors: Stacie B Dusetzina; Shellie Ellis; Rachel A Freedman; Rena M Conti; Aaron N Winn; James D Chambers; G Caleb Alexander; Haiden A Huskamp; Nancy L Keating
Journal: J Oncol Pract Date: 2015-06-09 Impact factor: 3.840

Review 2. Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.

Authors: Ana C Gregório; Manuela Lacerda; Paulo Figueiredo; Sérgio Simões; Sérgio Dias; João Nuno Moreira
Journal: Pathol Oncol Res Date: 2017-09-14 Impact factor: 3.201

3. Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration's Approval of Oncology Drugs.

Authors: Chul Kim; Vinay Prasad
Journal: Mayo Clin Proc Date: 2016-05-10 Impact factor: 7.616

Review 4. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.

Authors: Robert S Kerbel
Journal: J Mammary Gland Biol Neoplasia Date: 2012-09-26 Impact factor: 2.673

5. Targeting angiogenesis in metastatic breast cancer.

Authors: Sangeetha Reddy; Michael Raffin; Virginia Kaklamani
Journal: Oncologist Date: 2012-07-27

6. Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Authors: Maura N Dickler; William T Barry; Constance T Cirrincione; Matthew J Ellis; Mary Ellen Moynahan; Federico Innocenti; Arti Hurria; Hope S Rugo; Diana E Lake; Olwen Hahn; Bryan P Schneider; Debasish Tripathy; Lisa A Carey; Eric P Winer; Clifford A Hudis
Journal: J Clin Oncol Date: 2016-05-02 Impact factor: 44.544

7. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.

Authors: Bryan P Schneider; Robert J Gray; Milan Radovich; Fei Shen; Gail Vance; Lang Li; Guanglong Jiang; Kathy D Miller; Julie R Gralow; Maura N Dickler; Melody A Cobleigh; Edith A Perez; Tamara N Shenkier; Kirsten Vang Nielsen; Sven Müller; Ann Thor; George W Sledge; Joseph A Sparano; Nancy E Davidson; Sunil S Badve
Journal: Clin Cancer Res Date: 2013-01-22 Impact factor: 12.531

Review 8. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.

Authors: Bishal Gyawali; Spencer Phillips Hey; Aaron S Kesselheim
Journal: JAMA Intern Med Date: 2019-07-01 Impact factor: 21.873

9. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration.

Authors: Huseyin Naci; Katelyn R Smalley; Aaron S Kesselheim
Journal: JAMA Date: 2017-08-15 Impact factor: 56.272

10. Assessment of New Molecular Entities Approved for Cancer Treatment in 2020.

Authors: Claire E P Smith; Vinay Prasad
Journal: JAMA Netw Open Date: 2021-05-03